REG - Applied Nutrition - FY25 Trading Update

Applied NutritionAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250819:nRSS7968Va&default-theme=true

RNS Number : 7968V  Applied Nutrition PLC  19 August 2025

19 August 2025

 Applied Nutrition plc

(the "Group")

FY25 Trading Update and FY26 Outlook

FY25(1) results ahead of market expectations(2): revenue up c.24% and adjusted
EBITDA(3) up c.19% year-on-year

 

Applied Nutrition plc, a leading sports nutrition, health and wellness brand,
today announces an update on trading for the financial year ending 31 July
2025(1) and outlook for the financial year ending 31 July 2026(4).

 

FY25(1) Trading Update

 

Driven by strong second-half trading (approximately £60m of revenue), Group
revenue is expected to be ahead of market expectations(2), with revenue up 24%
year-on-year to approximately £107 million (FY24: £86 million) and adjusted
EBITDA(3) up approximately 19% year-on-year (FY24: £26m). Net cash (excluding
IFRS 16 liabilities) at the end of period is also expected to be ahead of
market expectations(2) at approximately £18.5 million.

 

The results for FY25 were achieved by the continued delivery of the Group's
multi-pillar, global growth strategy.

 

FY26 Outlook(4)

 

Following the strong recent trading and supported by the strategic progress,
the Group now expects revenue for the financial year ending 31 July 2026 to be
ahead of current market expectations(2).

 

The Board remains confident that the Group's core strengths, including its
B2B-focused business model, breadth of high-quality products and industry
leading new product development, will continue to drive sustained revenue
growth and strong profitability over the long-term.

 

Notice of Results

 

The Group expects to release its results for the year ended 31 July 2025 on,
or around, 10 November 2025.

 

Thomas Ryder, CEO of Applied Nutrition, said:

 

"We are proud to report that we have exceeded the guidance we gave at our IPO,
with our first full-year results expected to come in ahead of market
expectations. Our focus and ambition remain as strong as ever - in delivering
for our shareholders, customers and team - and we are excited about the
opportunities we have in the pipeline for the year ahead."

 

Notes:

(1) All figures used in this announcement relating to FY25 remain subject to
audit.

(2) Consensus market expectations for FY25 and FY26 before today were:

 Measure   FY25             FY26
 Revenue   £100.0 million   £112.4 million
 Net cash  £16.6 million    £31.5 million

( )

(3) Adjusted EBITDA excludes exceptional items. The only exceptional items are
expected to relate to the Group's Initial Public Offering ("IPO") during FY25.

(4) This announcement contains certain forward-looking statements. By their
nature, forward looking statements involve a number of risks, uncertainties or
assumptions that could cause actual results or events to differ materially
from those expressed or implied by those statements.  Forward looking
statements regarding past trends or activities should not be taken as
representation that such trends or activities will continue in the future.
Accordingly undue reliance should not be placed on forward looking statements.

For further information please contact:

 Applied Nutrition plc                                                         Via Alma

 Thomas Ryder, Chief Executive Officer

Steven Granite, Chief Operating Officer

Joe Pollard, Chief Financial Officer
 Alma Strategic Communications (Public Relations adviser to Applied Nutrition  +44 (0) 203 405 0205
 plc)

                                                                             appliednutrition@almastrategic.com
 Rebecca Sanders-Hewett, Sam Modlin, Joe Pederzolli, Sarah Peters

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation.  The person responsible for arranging the
release of this announcement on behalf of Applied Nutrition is Joe Pollard,
Chief Financial Officer.

Notes to editors

Applied Nutrition plc (LSE: APN) is a leading sports nutrition, health and
wellness brand, which formulates and creates nutrition products with a stated
aim of being the world's most trusted and innovative brand in the market.

Headquartered in the UK, the Group sells products in over 85 countries
worldwide and has a diverse product range, targeting elite athletes, gym goers
and health-conscious consumers. Applied Nutrition has developed and launched
four ranges under the umbrella of the Applied Nutrition brand - Applied
Nutrition, ABE, BodyFuel, and Endurance. Across the four ranges, the Group
sells over 100 different products.

Applied Nutrition's growth is fuelled by a market-leading product portfolio,
created and largely manufactured in-house at its Knowsley, Liverpool
headquarters by a team of industry experts. This end-to-end capability allows
the Group to innovate at speed, refresh and enhance existing products and
introduce new offerings that anticipate and respond to the latest consumer
trends.

Applied Nutrition largely operates a global business-to-business (B2B) model,
which has facilitated a low risk, highly cost-effective go-to-market strategy
and has enabled strong, profitable growth in the UK, Europe and other
international geographies. The business model and strategy has enabled the
Group to become a fast-growing, highly profitable and cash generative global
supplier in the sports nutrition, health and wellness market.

For further information, please visit www.appliednutritionplc.com
(http://www.appliednutritionplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBRGDIGDBDGUI